Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with FVC as the primary efficacy endpoint to evaluate its effectivenes
Epistemonikos ID: 4eff48bbf4b7fe6337bd76e06b3fbd027f048bfd
First added on: Feb 19, 2024